Rhythm Pharmaceuticals Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome
Rhythm Pharmaceuticals, Inc. (RYTM)
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rhythmtx.com
Company Research
Source: GlobeNewswire
BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced an Expanded Access Program (EAP) for setmelanotide for the treatment of eligible patients in the United States with severe obesity and hyperphagia due to Bardet-Biedl Syndrome (BBS). Rhythm expects to submit to the U.S. Food and Drug Administration (FDA) a supplemental new drug application (sNDA) for setmelanotide for the treatment of adult and pediatric patients 6 years of age and older with hunger and obesity due to BBS by the end of September. “BBS is a serious disease with significant unmet needs,” said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm. “Following the completion of our Phase 3 clinical trial and as we advance through the regulatory review process, we are pleased to make setmelanotide available through
Show less
Read more
Impact Snapshot
Event Time:
RYTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RYTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RYTM alerts
High impacting Rhythm Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RYTM
News
- Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024GlobeNewswire
- Cramer's Lighting Round: Sell Aspen Aerogels [CNBC]CNBC
- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target lowered by analysts at Wells Fargo & Company from $53.00 to $52.00. They now have an "overweight" rating on the stock.MarketBeat
- Rhythm Pharmaceuticals Announces New Employment Inducement GrantsGlobeNewswire
- Market Sentiment Around Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) [Yahoo! Finance]Yahoo! Finance
RYTM
Earnings
- 2/22/24 - In-Line
RYTM
Sec Filings
- 4/17/24 - Form SC
- 4/16/24 - Form 4
- 4/16/24 - Form 8-K
- RYTM's page on the SEC website